Pressure BioSciences, Inc. · OTC:PBIO
Pressure BioSciences — Investor Presentation (August 2016)
24 slides from Pressure BioSciences's investor presentation, August 2016
Slide 1: Investor Presentation August 2016
Investor Presentation Pressure BioSciences, Inc. (OTCQB: PBIO) Discovery Starts with Sample Preparation™ Investor Presentation August 2016
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward looking statements that reflect management’s current views and opinions as to the status of the Company’s products, technology and other future events and operations. These statements are neither a promise nor guarantee, but involve ri
Slide 3: Company Overview (OTCQB: PBIO)
Company Overview (OTCQB: PBIO) • 9 FT Staff; Near Boston, MA; Publicly Traded (OTCQB: PBIO) • 24 Patents: Pressure Cycling Technology (“PCT”) Platform • Develop, Mfg, & Sell PCT-based Instruments & Consumables • Initial Focus in Sample Preparation for the Research Market • ~ 275 PCT Systems Installe
Slide 4: Experienced Senior Management & Board
Experienced Senior Management & Board Management • Mr. Richard T. Schumacher, President & CEO Boston Biomedica (CEO, Founder); Panacos Pharma (President, Co-founder); Trinity Biotech (Founding Group); CBR Labs (Gen’l Mgr) - Harvard Medical School • Dr. Edmund Y. Ting, Senior Vice President of Engine
Slide 5: Primary Pressure Cycling Technology (PCT)
PrimaryPressure Sample Preparation CyclingforTechnology Biomolecular Analysis: (PCT) Cell Lysis 5
Slide 6: Sample Input Quality = Sample Result Quality
Sample Input Quality = Sample Result Quality Scientific research can be broken down to three key elements: sample preparation, analysis, & data reduction/interpretation “Discovery Starts with Sample Preparation” 6
Slide 7: Value Proposition: PCT-based Biological Sample Preparation
Value Proposition: PCT-based Biological Sample Preparation • Analysis of DNA, RNA, Proteins, & Lipids (“biomolecules”) is Crucial to the Discovery of New Biomarkers – Quality of Results Depends on the Quality of Preparation • Biological Sample Preparation is a Multi-Billion Market Comprised of an Es
Slide 8: Biomarker/Forensics Market: Estimated Size
Biomarker/Forensics Market: Estimated Size Estimated Market • Genomics (DNA/RNA) $7.1B in 2015 b • Next Gen Sequencing (DNA) $2.7B in 2017c • Mass Spectrometry (Proteins) $2.7B in 2011a,d • Forensic Tools and Products (DNA) $17.7B in 2019 e • Sample Prep for all OMICS: $8.4B in 2016 f • 500,000 Scie
Slide 9: Selected Marquee Customers (150)
Selected Marquee Customers (150) 9
Slide 10: PCT Sample Preparation System Just Released
PCT Sample Preparation System Just Released ‼ Barocycler™ NEP2320 PULSE Tube Barocycler™ 2320 EXTREME MicroTubes PCT-dependent Kits 10
Slide 11: Barozyme: New High-throughput PCT-based System
Barozyme: New High-throughput PCT-based System Barozyme HT48 Evaluation (KOLs) 2014/15 Marketing Focus Increase Planned For 2H 2016 • Initial Application: – High pressure digestion • Consumable: – Proprietary 8-well strips • Number of Samples: – 48 samples 11
Slide 12: PCT Platform: Enabling the Enablers
PCT Platform: Enabling the Enablers Eight Impact Areas Where PBI’s Powerful and Enabling PCT Platform is Currently Being Used… and the Early Results are Very Exciting & Significant 1. Agriculture/Food Science 2. Environmental Epidemiology 3. Anti-Bioterror 4. Rational Drug Design 5. Biomarker Discov
Slide 13: Anti-bioterrorism
Anti-bioterrorism Dr. Bradford Powell • Director Analytical Sciences, PharmAthene • Previously Division of Bacteriology, US Army Medical Research Institute of Infectious Diseases (USAMRIID) Inactivation and Extraction of Bacterial Spores for Systems Biological Analysis Sample Preparation in Biologic
Slide 14: Rational Drug Design and Development
Rational Drug Design and Development Professor Wayne L. Hubbell • Distinguished Professor of Biochemistry: UCLA • Member, National Academy of Sciences • Fellow, American Academy of Arts and Sciences Structure-Relaxation Mechanism for the Response of T4 Lysozyme Cavity Mutants to Hydrostatic Pressure
Slide 15: Biomarker Discovery
Biomarker Discovery Professor Jennifer Van Eyk • Professor of Medicine, Cedars-Sinai Med. Ctr. • Director, Basic Science Research, the Barbara Streisand Women’s HC Improved protein extraction and identification from archival formalin-fixed paraffin-embedded human aortas. Proteomics Clin. Appl. April
Slide 16: Non-invasive Fecal Lipidomic Profiling
Non-invasive Fecal Lipidomic Profiling Professor Bruce Kristal • Neuroscientist, Brigham and Women's Hospital, Boston • Associate Professor of Neurosurgery, Harvard MS • Molecular Biologist, Expert in Metabolomics Method Development for Fecal Lipidomics Profiling Anal. Chem. 2012 • Robust methodolog
Slide 17: Improved Rape Kit Testing
Improved Rape Kit Testing Professor Bruce McCord • Professor of Analytical/Forensic Chemistry, FIU • Over 75 peer reviewed papers and 11 book chapters The application of alkaline lysis and PCT in the differential extraction of DNA from sperm and epithelial cells recovered from cotton swabs Analytica
Slide 18: Personalized Medicine: Analysis of Tissue Biopsies
Personalized Medicine: Analysis of Tissue Biopsies Professor Ruedi Aebersold • Professor of Systems Biology, Institute of Molecular Systems Biology (IMSB), ETH Zurich • Scientific Advisory Committee of numerous public and private research organizations; member of several editorial boards in proteomi
Slide 19: Mr. David Weild IV
Mr. David Weild IV • Founder, Chairman, and CEO, IssuWorks • CEO, Weild & Co Holdings (Inv Banking Firm) • Former Vice-Chairman of NASDAQ • Former Head of Global Equity Transactions, Prudential Securities • Former President, PrudentialSecurities.com • Former Head, Capital Markets Group of Grant Thor
Slide 20: Key Achievements: 2015
Key Achievements: 2015 • Awarded Two-Year $1M NIH Grant (DNA Shearing) • New PCT Consumable (µPestle) for Small Tissue Biopsy Processing • Prof Aebersold & Team Publish on PCT-SWATH in Nature Medicine • Dr. McCord and Team Publish on Improved Rape Kit Test Progress • Published Scientific Articles Sh
Slide 21: Key Achievements: 2016
Key Achievements: 2016 • Company Closes Over-Subscribed $5M PIPE at $6.3M • Q1 Products Revenue Incr. 26%, Total Revenue Incr. 16% YoY • 100% (almost $3M) of all Variable Rate Debt Eliminated • Co-Marketing Partner Announced (Jan): SCIEX! • Global leader in life sciences analytical technologies • Ma
Slide 22: Children's Medical Research Institute (Australia)
Children’s Medical Research Institute (Australia) SCIEX Announces Alliance with CMRI on Feb 3, 2016 CMRI Designated Official Collaborator – US Cancer Moonshot – by VP Joe Biden on July 16, 2016 •CMRI will generate proteomic profiles on 70,000 tumor samples in 7 years •CMRI has received a $10M grant
Slide 23: Initial Commercial Application: Mass Spectrometry
Initial Commercial Application: Mass Spectrometry The Following Information is for Discussion Purposes Only – Not Guidance Biomarker Discovery (Enhanced Mass Spectrometry Sample Preparation) We Believe: • there are approx 16,000 MS labs worldwide (8,000 U.S.); approx 50% do protein analysis • most M
Slide 24: Short-term Growth Drivers
Short-term Growth Drivers • Jan 12th: SCIEX, a Major WW Proteomics Mass Spec Player, announced an Exclusive, 2-Year, Worldwide, Co-Marketing Agreement with PBI • 100% of Floorless Debt Eliminated – “Much Cleaner Balance Sheet” • 2H 2016 M$S Expansion: 2-4 Additions in Sales & Marketing • Company Exp
Pressure BioSciences — Investor Presentation (August 2016) on 6ix